Hemoadsorption in the Management of Septic Shock: A Systematic Review and Meta-Analysis
Top Cited Papers
Open Access
- 27 March 2025
- journal article
- review article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (7) , 2285
Abstract
Background/Objectives: Septic shock remains a significant clinical challenge with consistently high mortality rates. Recent investigations have focused on the efficacy of CytoSorb® (CytoSorbents Corporation, Monmouth Junction, NJ, USA), an extracorporeal cytokine adsorber, and how it impacts outcomes in sepsis. The current meta-analysis reports on the impact of CytoSorb® on survival, specifically in septic shock patients. Methods: We conducted a comprehensive systematic search across the PubMed and COCHRANE databases for studies published up to 10 June 2024. The analysis prioritized randomized controlled trials and observational studies with control groups involving septic shock patients while excluding case reports and case series. Nine studies were finally included in our meta-analysis following the initial screening of 115 articles after excluding duplicates and irrelevant entries. Results: The meta-analysis was performed on 744 critically ill patients with septic shock from one RCT and eight observational studies. Of these, 449 patients received treatment with CytoSorb® in addition to standard care. Our data indicate that CytoSorb® use is associated with reduced in-hospital mortality, evidenced by an odds ratio (OR) of 0.64 [0.42; 0.97] and a p-value of 0.036. For 28–30-day mortality, the findings were more pronounced with an OR of 0.46 [0.28; 0.78] and a p-value of 0.003. The analysis of the longest observed mortality showed a trend for improved survival within the CytoSorb group; however, it did not reach statistical significance. Additionally, there was a significant improvement in hemodynamic stability as a secondary endpoint, as evidenced by notable reductions in vasopressor requirements in the hemoadsorption group. Conclusions: The current meta-analysis suggests that the use of CytoSorb® alongside standard of care management may be linked to improved short-term survival in patients with septic shock; however, these findings should be interpreted with caution in light of the heterogeneity and the modest quality of the studies included. Prospective studies are needed to better determine the impact of hemoadsorption on shock reversal and survival in these critically ill patients.Keywords
Funding Information
- CytoSorbents Europe GmbH
This publication has 41 references indexed in Scilit:
- RoB 2: a revised tool for assessing risk of bias in randomised trialsBMJ, 2019
- Extracorporeal cytokine adsorption in septic shock: A proof of concept randomized, controlled pilot studyJournal of Critical Care, 2019
- The effect of a novel extracorporeal cytokine hemoadsorption device on IL-6 elimination in septic patients: A randomized controlled trialPLOS ONE, 2017
- Agents to reduce cytokine stormF1000Research, 2016
- ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventionsBMJ, 2016
- Neutrophils in the activation and regulation of innate and adaptive immunityNature Reviews Immunology, 2011
- Cytokine Removal with a Novel Adsorbent PolymerBlood Purification, 2004
- Hemoadsorption removes tumor necrosis factor, interleukin-6, and interleukin-10, reduces nuclear factor-κB DNA binding, and improves short-term survival in lethal endotoxemia*Critical Care Medicine, 2004
- Sorbents in Acute Renal Failure and the Systemic Inflammatory Response SyndromeBlood Purification, 2003
- Statistical Aspects of the Analysis of Data From Retrospective Studies of DiseaseJNCI: Journal of the National Cancer Institute, 1959